Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2016 - 2026)

Supernus Pharmaceuticals (SUPN) reported Long-Term Deferred Tax of $30.8 million for Q1 2026, down 19.64% quarter-over-quarter from $38.4 million in Q4 2025.

Supernus Pharmaceuticals (SUPN) Long-Term Deferred Tax (2016 - 2026) Analysis & Trends

Supernus Pharmaceuticals (SUPN) has 7 years of Long-Term Deferred Tax data on file, last reported at $30.8 million in Q1 2026.

  • Long-Term Deferred Tax for Q1 2026 came in at $30.8 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $30.8 million (changed N/A YoY), and the FY2025 annual result was $38.4 million, changed N/A from the prior year.
  • Long-Term Deferred Tax slipped to $30.8 million in Q1 2026 per SUPN's latest filing, from $38.4 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $38.4 million in Q4 2025 and troughed at $6.2 million in Q2 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn
10 Supernus Pharmaceuticals 2.63 Bn 2.24 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2026 30.82 Mn
Dec 31, 2025 38.35 Mn
Sep 30, 2025 8.79 Mn
Jun 30, 2025 6.18 Mn
Mar 31, 2020 34.07 Mn
Dec 31, 2019 32.06 Mn
Sep 30, 2019 27.95 Mn
Jun 30, 2019 25.98 Mn
Mar 31, 2019 27.97 Mn
Dec 31, 2018 29.68 Mn
Sep 30, 2018 31.37 Mn
Jun 30, 2018 25.53 Mn
Mar 31, 2018 26.25 Mn
Dec 31, 2017 20.84 Mn
Sep 30, 2017 28.81 Mn
Jun 30, 2017 30.45 Mn
Mar 31, 2017 37.86 Mn
Dec 31, 2016 41.73 Mn
Sep 30, 2016 42.26 Mn